Answers are grounded in this paper and cite their sources.
Systematic review evaluates AI's non-invasive prediction of MGMT methylation in glioblastoma, suggesting improved diagnostics.
Purpose: Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis. O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation is a critical biomarker for guiding chemotherapy decisions, yet current testing requires invasive tissue sampling. This study aimed to systematically evaluate the diagnostic accuracy of artificial intelligence (AI) models using MRI for non-invasive prediction of MGMT promoter methylation status in GBM.
No takes yet. Share an insight, caveat, or question.
Khoursheed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: